GlassScriptPhysician profile
Jonathan B Berger
NPI 1336237031
$707.23
in general payments reported to CMS, 2019-2025
15 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.43 · 2021: $14.52 · 2022: $118 · 2023: $24.08 · 2024: $124 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $133.07 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $103.01 | 2022-2025 | |
| Pfizer INC. | $90.57 | 2022-2024 | |
| Saluda Medical Americas, INC. | $72.91 | 2025 | Evoke |
| Glaxosmithkline, LLC. | $61.25 | 2025 | Shingrix, Arexvy |
| Medicure Pharma INC. | $45.05 | 2025 | Zypitamag |
| Amgen INC. | $35.50 | 2022-2025 | Otezla, Repatha |
| Novo Nordisk INC | $34.99 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.93 | 2019 | |
| Esperion Therapeutics, INC. | $20.93 | 2024 | Nexletol |
| Intra-Sana Laboratories | $20.90 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Bausch Health US, LLC | $20.50 | 2019 | |
| Heartflow, INC. | $15.95 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.15 | 2024 | Livalo |
| Neurelis, INC. | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.